-
Lazertinib
- names:
Lazertinib
- CAS号:
1903008-80-9
MDL Number: - MF(分子式): C30H34N8O3 MW(分子量): 554.64
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | |
| 英文别名 | Lazertinib |
| CAS号 | 1903008-80-9 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C30H34N8O3 |
| 分子量 Molecular Weight | 554.64 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度9 mg/mL(16.23 mM;Need ultrasonic) |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
| 产品说明 | |
| Introduction | Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generationEGFRtyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. |
| Application1 | |
| Application2 | |
| Application3 |
Lazertinib 是一种有效的,可逆,可口服,可透过血脑屏障的,突变体选择性的第三代EGFR酪氨酸激酶抑制剂,可用于非小细胞肺癌的研究。Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generationEGFRtyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer.
| 【1】.Byoung Chul Cho, et al. YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results. |
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


